Based on the results, NeuVax, also called nelipepimut-S, is in phase III of testing [86, 87]
The peptide also demonstrates favorable effects on cardiovascular risk factors including blood pressure, lipid profiles, and inflammatory markers
References Regan JP, Casaubon JT
How does Flow Wellness approach GLP-1 microdosing
Beyond T2D and weight management in individuals with overweight or obesity, GLP-1 receptor agonists are approved for metabolic dysfunction associated steatohepatitis in people with moderate or advanced fibrosis, obstructive sleep apnea in obese adults, reduction of major adverse cardiovascular events in adults with T2D and cardiovascular disease (CVD), and slowing progression of chronic kidney disease and cardiovascular mortality in adults with both chronic kidney disease and T2D